IVERIC bio, Inc. (ISEE) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Parsippany, NJ, United States. Der aktuelle CEO ist Glenn P. Sblendorio.
ISEE hat IPO-Datum 2013-09-25, 163 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.51B.
IVERIC bio, Inc. is a biopharmaceutical company focused on discovering and developing novel treatments for retinal diseases, particularly age-related macular degeneration and orphan inherited retinal diseases. The company's lead program, Zimura (an inhibitor of complement factor C5), is in Phase 3 clinical trials for geographic atrophy secondary to dry age-related macular degeneration, with earlier-stage candidates including STAR for leber congenital amaurosis and autosomal recessive stargardt disease, and IC-500, IC-100, and IC-200 targeting various inherited retinal conditions. IVERIC bio maintains a robust pipeline of programs in various clinical and preclinical stages, supported by gene therapy approaches including miniCEP290, miniABCA4, and miniUSH2A programs. Incorporated in 2007 and based in Parsippany, New Jersey, the company was formerly known as Ophthotech Corporation before rebranding in April 2019.
